From the Journals

Low-Dose Rivaroxaban Did Not Reduce LV Thrombus After Anterior STEMI

Adding low-dose rivaroxaban to dual antiplatelet therapy following anterior myocardial infarction did not reduce cardiac MRI–detected left ventricular thrombus at 1 month and increased minor bleeding in a 560-patient randomized trial.

Share

In the APERITIF trial, conducted across 29 French centers, researchers assessed the impact of adding low-dose rivaroxaban to dual antiplatelet therapy in patients with anterior ST-segment elevation myocardial infarction. The study found no significant reduction in left ventricular thrombus rates at one month compared to dual antiplatelet therapy alone (14% vs. 17%, respectively). The trial also noted a higher incidence of any bleeding with rivaroxaban. Key limitations were acknowledged, such as the open-label design and fewer thrombus events than anticipated, impacting statistical power.

Original Source(s)

Low-Dose Rivaroxaban Did Not Reduce LV Thrombus After Anterior STEMI

Adding low-dose rivaroxaban to dual antiplatelet therapy following anterior myocardial infarction did not reduce cardiac MRI–detected left ventricular thrombus at 1 month and increased minor bleeding in a 560-patient randomized trial.

  • by Doug Brunk

  • March 4, 2026

  • 3 min

Related Content

Quality of Life in Cardiac Arrest Recovery

Post–cardiac arrest care is increasingly structured around survivorship, with standardized patient-reported assessments supporting multidisciplinary follow-up.

Back on the Golf Course in Three Weeks After Minimally Invasive Bypass Surgery

Like many individuals with heart disease, Mr. Zells had no idea there was a serious issue with his heart. “I didn’t know I had any problem at all,” he recalls.

  • by

  • February 11, 2026

  • 9 min
AHA Issues Statement on ACS in Young Women

Knowledge and outcome gaps in premenopausal women with acute coronary syndrome demand tailored approaches to diagnosis and care